Company intelligence / Profile preview

Jazz Pharmaceuticals plc

Ownership: Public · JAZZ
Employees: ~2800
Development stage: Commercial

Overview

Jazz Pharmaceuticals has multiple FDA-approved products on the market including Xyrem, Xywav, Vyxeos, Defitelio, and others. The company has a diverse portfolio of marketed medicines for sleep disorders and epilepsy, and a growing portfolio of cancer treatments.

Therapeutic areas: OncologyPsychiatryNeurology
Modalities: Small moleculesbispecific antibodies
Industry: Biotech

Drug pipeline

60 assets

Asparaginase erwinia chrysanthemi

Approved

59 more assets in the full pipeline.

Request access →

Partnerships

Zymeworks Inc.Werewolf Therapeutics, Inc.Sumitomo Pharma Co., Ltd.Redx PharmaCodiak BioSciencesLife Science Cares

Financials

Market cap: $15.2B
Total revenue: $1.2B
Enterprise value: $17.4B

Beyond the preview

Go deeper on Jazz Pharmaceuticals plc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jazz Pharmaceuticals plc.

Explore the full profile